Merck & Co Inc (MRK)
101.88
-0.44
(-0.43%)
USD |
NYSE |
Nov 01, 16:00
101.94
+0.06
(+0.06%)
After-Hours: 20:00
Merck Enterprise Value: 284.75B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 284.75B |
| October 31, 2024 | 285.86B |
| October 30, 2024 | 292.22B |
| October 29, 2024 | 289.44B |
| October 28, 2024 | 290.70B |
| October 25, 2024 | 290.07B |
| October 24, 2024 | 294.89B |
| October 23, 2024 | 296.15B |
| October 22, 2024 | 296.81B |
| October 21, 2024 | 296.05B |
| October 18, 2024 | 302.03B |
| October 17, 2024 | 304.70B |
| October 16, 2024 | 306.39B |
| October 15, 2024 | 309.21B |
| October 14, 2024 | 304.54B |
| October 11, 2024 | 304.64B |
| October 10, 2024 | 303.81B |
| October 09, 2024 | 306.01B |
| October 08, 2024 | 301.58B |
| October 07, 2024 | 301.75B |
| October 04, 2024 | 304.75B |
| October 03, 2024 | 305.79B |
| October 02, 2024 | 310.60B |
| October 01, 2024 | 317.34B |
| September 30, 2024 | 314.35B |
| Date | Value |
|---|---|
| September 27, 2024 | 314.68B |
| September 26, 2024 | 313.16B |
| September 25, 2024 | 317.32B |
| September 24, 2024 | 317.90B |
| September 23, 2024 | 319.60B |
| September 20, 2024 | 323.50B |
| September 19, 2024 | 323.66B |
| September 18, 2024 | 327.23B |
| September 17, 2024 | 326.34B |
| September 16, 2024 | 325.51B |
| September 13, 2024 | 320.18B |
| September 12, 2024 | 318.64B |
| September 11, 2024 | 317.27B |
| September 10, 2024 | 318.84B |
| September 09, 2024 | 319.04B |
| September 06, 2024 | 325.20B |
| September 05, 2024 | 327.10B |
| September 04, 2024 | 320.03B |
| September 03, 2024 | 322.01B |
| August 30, 2024 | 326.75B |
| August 29, 2024 | 324.24B |
| August 28, 2024 | 324.09B |
| August 27, 2024 | 321.81B |
| August 26, 2024 | 321.22B |
| August 23, 2024 | 322.06B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
176.33B
Minimum
Mar 23 2020
365.42B
Maximum
Jun 24 2024
259.10B
Average
240.87B
Median
Dec 23 2019
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Johnson & Johnson | 400.99B |
| Eli Lilly and Co | 805.11B |
| Pfizer Inc | 221.03B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.157B |
| Revenue (Quarterly) | 16.66B |
| Total Expenses (Quarterly) | 12.67B |
| EPS Diluted (Quarterly) | 1.24 |
| Gross Profit Margin (Quarterly) | 75.51% |
| Profit Margin (Quarterly) | 18.95% |
| Earnings Yield | 4.68% |
| Operating Earnings Yield | 5.47% |
| Normalized Earnings Yield | 4.822 |